Literature DB >> 29519170

DRESS syndrome: a detailed insight.

Sapan Kumar Behera1, Saibal Das1, Alphienes Stanley Xavier1, Sandhiya Selvarajan1.   

Abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a serious and potentially fatal adverse effect to therapeutic medications. The incidence of this condition varies among different ethnicities because of the difference in the genetic makeup. Though fever, rash and eosinophilia are essential features for the diagnosis of this syndrome, these vary from patient to patient along with the involvement of various organs such as liver, kidney, lungs, pancreas, etc. Some of the atypical features are dysphagia, agranulocytosis, and chylous ascites. Phenytoin, phenobarbitone, carbamazepine, and allopurinol are the most common drugs responsible for developing this syndrome, although the list is fairly long. Among the criteria used for the diagnosis of DRESS syndrome, European Registry of Severe Cutaneous Adverse Reactions to Drugs and Collection of Biological Samples (RegiSCAR) criteria is the most commonly used one. The management of this syndrome involves early removal of the causative agent and treatment with anti-histamines and emollients in the mild form, corticosteroids in the moderate form and plasmapheresis in the severe form along with other alternatives drugs. Healthcare professionals should be more vigilant about the early manifestations of this syndrome, as early diagnosis and treatment improve outcomes considerably.

Entities:  

Keywords:  Corticosteroids; drug reaction with eosinophilia and systemic symptoms (DRESS); genetic predispositions viral reactivation; hypersensitivity; immune-allergic reaction

Mesh:

Substances:

Year:  2018        PMID: 29519170     DOI: 10.1080/21548331.2018.1451205

Source DB:  PubMed          Journal:  Hosp Pract (1995)        ISSN: 2154-8331


  7 in total

1.  A fatal presentation of DRESS syndrome with multiple visceral failure mimicking septic shock.

Authors:  Mohammed Amine Lafkih; Hamza Mimouni; Mohammed Azizi; El Kaouini Abderrahim; Mohammed Maarad; Bkiyar Houssam; Brahim Housni
Journal:  Ann Med Surg (Lond)       Date:  2022-06-28

Review 2.  [Differential diagnosis of hypereosinophilia].

Authors:  J C Henes; S Wirths; B Hellmich
Journal:  Z Rheumatol       Date:  2019-05       Impact factor: 1.530

Review 3.  Case Reports of DRESS Syndrome and Symptoms Consistent with DRESS Syndrome Following Treatment with Recently Marketed Monoclonal Antibodies.

Authors:  James C Di Palma-Grisi; Kesav Vijayagopal; Muhammad A Muslimani
Journal:  Autoimmune Dis       Date:  2019-06-09

4.  Drug reaction with eosinophilia and systemic symptoms (DRESS) with severe and atypical lung involvement.

Authors:  Diego Armando Guerrero Gómez; Sara París Zorro; Wilmer Aponte Barrios; Jorge Alberto Carrillo Bayona
Journal:  Radiol Case Rep       Date:  2020-09-04

5.  Stevens-Johnson Syndrome in a Patient of Color: A Case Report and an Assessment of Diversity in Medical Education Resources.

Authors:  Darlene Diep; Bineetha Aluri; Alison Crane; Kathleen Miao; Kamilah S Kannan; Robert Goldsteen
Journal:  Cureus       Date:  2022-02-15

6.  Case Report: Adult Still's Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient.

Authors:  Julia Krämer; Tanja Krömer-Olbrisch; Heinz-Jürgen Lakomek; Peter D Schellinger; Dirk Foell; Sven G Meuth; Vera Straeten
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

7.  Drug reaction with eosinophilia and systemic symptoms (DRESS) in children.

Authors:  Francesca Mori; Carlo Caffarelli; Silvia Caimmi; Paolo Bottau; Lucia Liotti; Fabrizio Franceschini; Fabio Cardinale; Roberto Bernardini; Giuseppe Crisafulli; Francesca Saretta; Elio Novembre
Journal:  Acta Biomed       Date:  2019-01-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.